Although limited to human macrophages, in our study, the high efficacy of GSK3β inhibitors in an ex vivo infection model, together with our genetic validation studies, merit serious consideration of further development of HDTs against intracellular pathogens such as Mtb, as alternative or supplemental therapies to antibiotics. Here, GSK3B is linked to infection.